23 April 2026

9 min read

Reviewed 4 May 2026

Elicit vs Consensus in 2026 — Which AI Research Tool for Biomedical Literature?

Elicit and Consensus are the two most popular AI research assistants in 2026. They solve different problems: Elicit is a structured-extraction workflow for building evidence tables across papers; Consensus is an answer engine that returns evidence-weighted verdicts on binary claims. This is a neutral comparison — with sources — plus a short note on BioSkepsis as a biomedical-native third option.

At-a-glance: Elicit vs Consensus for biomedical research

Feature comparison — Elicit, Consensus, and BioSkepsis for biomedical literature
Feature	Elicit	Consensus	BioSkepsis
Primary job	Structured extraction tables across papers	Yes/no evidence questions + Consensus Meter	Biomedical research engine (landscape, mechanism, lab-result interpretation)
Domain focus	All academic fields; strong on RCTs	All scientific disciplines	Biomedical & life-science native
Paper corpus	138M papers + 545K clinical trials	200M+ papers (Semantic Scholar)	40M+ curated biomedical papers
Retrieval model	Semantic similarity over academic corpus	Semantic similarity over broad science corpus	Biology-native knowledge graph (GO + MeSH + genes)
Full-text reasoning	Full-text on Pro tier	Snapshot summaries; deeper on paid tiers	Full-text over methods, controls, supplementary (Plus+)
Structured extraction	Flagship feature	Not a primary feature	Mechanistic-links table (Plus+)
Systematic review workflow	Guided flow (search → screen → extract → report)	Not optimised for exhaustive review	Research landscape + smart select
Lab-result interpretation	No	No	Upload notes → mapped against literature
Free tier	One-time credits (see vendor)	Monthly caps (see vendor)	Ongoing, 100 papers/session
Citations grounded	Yes	Yes	Yes (declines when evidence insufficient)

Elicit — structured extraction for biomedical systematic reviews

Elicit's signature workflow is column extraction: you define a set of fields — sample size, intervention, effect size, limitations, outcome measure — and Elicit populates a spreadsheet row for each of 50–500 papers. It is the most mature instance of this pattern on the market and a strong fit for systematic reviews that span multiple disciplines.

The corpus is the broadest on this comparison: 138M papers plus 545K clinical trials from ClinicalTrials.gov. Elicit also offers a guided systematic-review flow — search → screen → extract → report — that maps onto the PRISMA workflow more closely than any other AI tool. Blaizot et al. (2022) reviewed AI methods in health-science systematic reviews and found that screening and extraction were the most common stages where AI tools were deployed (PMID: 35174972); Elicit covers both.

Limitations for biomedical researchers: Elicit treats biomedical papers with the same retrieval model as papers in any other field. There is no biology-specific ontology weighting — a query about mTOR autophagy retrieves text-similar papers, not biologically connected ones. Full-text analysis is restricted to higher tiers. The free tier is credit-based rather than ongoing.

When Elicit is the right choice for biomedical work

You are running a systematic review of 12 RCTs comparing GLP-1 receptor agonists for weight loss in adults with type 2 diabetes, and you need a table of sample sizes, baseline HbA1c, treatment durations, primary endpoints, and effect sizes. Elicit's column-extraction workflow populates this table across all 12 papers in minutes. No other tool on this comparison does this as well.

Consensus — evidence-weighted answers for biomedical claims

Consensus is optimised for a specific, valuable question shape: does X cause Y? You ask a yes/no research question and Consensus returns a ranked list of papers, each tagged as supporting, contradicting, or inconclusive, along with a top-line Consensus Meter showing overall evidence balance. It is the fastest way to get a defensible read on whether the biomedical literature currently leans for or against a claim.

The corpus is the largest in raw count: approximately 200M papers via Semantic Scholar. The Consensus Meter is genuinely novel — neither Elicit nor BioSkepsis provides an aggregated evidence verdict in the same visual format. Good for clinicians, science journalists, policy analysts, and anyone who needs a literature-backed answer fast.

Limitations for biomedical researchers: Consensus is optimised for binary or comparative claims, not for exploratory discovery, mechanism-level reasoning, or column extraction. It does not offer lab-note interpretation. Coverage is broad but not biology-specific — there is no Gene Ontology or MeSH weighting.

When Consensus is the right choice for biomedical work

You are a clinician and a patient asks whether metformin reduces cancer risk. You need a defensible answer in two minutes, not a systematic review. Consensus returns a Meter showing the evidence balance across relevant studies with inline citations — supporting, contradicting, inconclusive. This is exactly the question shape Consensus was designed for.

BioSkepsis — the biology-native third option for biomedical research

Neither Elicit nor Consensus was built for biology. Both are generalist tools that happen to cover biomedical literature; neither has a biology-specific retrieval model. BioSkepsis is purpose-built for biology, medicine, pharma, biotech, and agricultural/veterinary/environmental science.

The retrieval model is a biology-native knowledge graph that weights Gene Ontology terms, MeSH descriptors, gene symbols, and pathway relationships. A query about "mTOR autophagy in colorectal cancer" returns papers biologically connected to that axis — including work on ULK1-AMPK signalling, TFEB-driven lysosomal biogenesis, and Beclin-1 complex regulation — not just text-similar papers about cancer.

Three features that neither Elicit nor Consensus offers: full-text reasoning over methods, controls, and supplementary material (not just abstracts); lab-result interpretation — upload experimental notes and map them against published evidence; and explicit "insufficient evidence" responses when the literature does not support a claim, rather than generating a plausible-looking summary.

Limitations, honestly: BioSkepsis is not the tool for economics, education, or policy studies. Its column-extraction workflow is less mature than Elicit's flagship feature. Its evidence-verdict format is not as visual as Consensus's Meter.

When BioSkepsis is the right choice over Elicit or Consensus

You are a molecular biologist studying whether MFN2 loss-of-function causes axonal degeneration in peripheral neurons. This is a mechanism question, not a yes/no claim and not a column-extraction task. You need retrieval that understands Mitofusin-2, mitochondrial fission, CMT2A, and the DRP1-MFF axis — functionally related terms that neither Elicit's nor Consensus's generalist retrieval model weights. BioSkepsis's biology-native knowledge graph retrieves across these relationships.

Which AI research tool to pick for biomedical literature

ElicitSystematic reviewers building extraction tables across biomedical RCTs

You need to extract sample sizes, effect sizes, methods, and limitations across 20+ papers into a structured table. Your review spans multiple fields or requires a guided search → screen → extract → report workflow. Elicit's column-extraction feature is the most mature on the market.

ConsensusClinicians and policy analysts fact-checking biomedical claims

You need a fast, defensible yes/no answer to a clinical or policy claim — does X cause Y, does treatment A outperform treatment B. The Consensus Meter gives you an aggregated evidence verdict in seconds. Ideal for lightweight evidence checks, not deep synthesis.

BioSkepsisLife-science researchers asking mechanism or pathway questions

You work in biology, medicine, pharma, or biotech. Your questions are about genes, pathways, and mechanisms — not binary claims. You want retrieval weighted by Gene Ontology + MeSH. You may also want to upload lab results and interpret them against published evidence. The free tier (100 papers/session, no time limit) lets you validate before paying.

All threeBiomedical teams running comprehensive literature programmes

Use Consensus for quick claim-checking. Use Elicit for structured extraction across your included set. Use BioSkepsis for biology-native discovery and mechanism-level questions. Most serious biomedical researchers end up using two or three tools — the goal is the right tool for the task, not one tool to rule them all.

Free tiers: Elicit vs Consensus vs BioSkepsis for biomedical researchers

Free-tier comparison — Elicit, Consensus, and BioSkepsis
Tool	Free tier type	Practical cap	Notes
Elicit	One-time credit pool + monthly report cap	Capped; credit-based	Suited for occasional use; regular users need a paid plan
Consensus	Unlimited basic search + monthly Pro Analysis cap	Monthly cap on deep analyses	Basic search is usable; Pro features capped
BioSkepsis Basic	Ongoing free tier	100 papers/session	No credit card, no time limit; paid tiers for extraction tables and higher throughput

All three vendors update pricing regularly. To avoid stale numbers we link to live pricing pages: elicit.com/pricing, consensus.app/pricing, bioskepsis.ai/pricing.

Frequently asked questions

What is the main difference between Elicit and Consensus for biomedical research?

Elicit is a structured-extraction workflow: you define columns (sample size, effect size, methods) and it populates a spreadsheet across 20–500 papers. Consensus is an answer engine: you ask a yes/no claim and it returns an evidence-weighted verdict with a visual Consensus Meter. Elicit is for building evidence tables; Consensus is for fast fact-checking. Neither has biology-specific ontology weighting — for that, BioSkepsis is the biomedical-native option.

Which has more papers — Elicit or Consensus?

Consensus indexes approximately 200M papers via Semantic Scholar. Elicit indexes 138M papers plus 545K clinical trials from ClinicalTrials.gov. Consensus has broader raw coverage; Elicit has dedicated clinical-trial integration. BioSkepsis indexes 40M+ curated biomedical papers — smaller in total count but deeper in biomedical domain coverage with Gene Ontology and MeSH weighting.

Which is better for biomedical systematic reviews — Elicit or Consensus?

Elicit. Its guided search → screen → extract → report workflow is specifically designed for systematic reviews, and its column-extraction feature is the most mature on the market. Consensus is optimised for binary claim-checking, not exhaustive evidence synthesis. For biomedical systematic reviews specifically, BioSkepsis adds biology-native retrieval that catches papers Elicit's generalist model may miss.

Is Elicit or Consensus cheaper for biomedical researchers?

Both vendors update pricing regularly, so we link to their live pricing pages rather than printing dollar amounts that may go stale. Both offer free tiers: Elicit's is a one-time credit pool; Consensus offers monthly caps on Pro Analyses. BioSkepsis Basic is ongoing-free with 100 papers per session and no time limit. Check each vendor's pricing page for current terms.

Which hallucinates less — Elicit or Consensus?

Both are retrieval-grounded tools that cite indexed papers rather than generating references from training data, so their hallucination rates are substantially lower than general-purpose chatbots — where one study found 16% of ChatGPT-4 biomedical references were completely fabricated (PMID: 38619763). Neither vendor publishes a formal hallucination benchmark. BioSkepsis adds explicit "insufficient evidence" responses when the literature does not support a claim.

Can I use Elicit and Consensus together for biomedical research?

Yes, and many researchers do. A practical workflow: use Consensus to get a quick evidence-weighted verdict on a binary claim, then use Elicit to extract structured data across the papers Consensus surfaced. For biomedical work, add BioSkepsis to the pipeline for biology-native retrieval that catches mechanistically related papers both tools may miss.

I work in biology or medicine — should I use Elicit, Consensus, or BioSkepsis?

If your questions are mechanistic or pathway-level, BioSkepsis is the strongest fit — its biology-native knowledge graph weights Gene Ontology terms, MeSH descriptors, and gene symbols. If you need structured extraction across 50+ papers for a systematic review, add Elicit. If you need a fast yes/no evidence check, add Consensus. Most biomedical researchers use two or three tools in combination.

Researching biomedical literature? Try BioSkepsis free.

Biology-native knowledge graph (Gene Ontology + MeSH) across 40M+ curated biomedical papers. Free tier with 100 papers per session, full-text reasoning, lab-result interpretation, Zotero sync.

Start free

Sources & further reading

Blaizot A, Veettil SK, Saidoung P, et al. Using artificial intelligence methods for systematic review in health sciences: a systematic review. Res Synth Methods. 2022;13(3):353–362. PMID: 35174972. doi:10.1002/jrsm.1553
Safrai M, Orwig KE. Utilizing artificial intelligence in academic writing: an in-depth evaluation of a scientific review on fertility preservation written by ChatGPT-4. J Assist Reprod Genet. 2024;41(7):1871–1880. PMID: 38619763. doi:10.1007/s10815-024-03089-7
Elicit official pricing — elicit.com/pricing
Consensus official pricing — consensus.app/pricing
BioSkepsis pricing — bioskepsis.ai/pricing
HKUST Library: Trust in AI evaluation — library.hkust.edu.hk

"Elicit" and "Consensus" are trademarks of their respective owners and are used here for identification and comparison only under the doctrine of nominative fair use. BioSkepsis is not affiliated with, endorsed by, or sponsored by either vendor. All product claims are sourced from public vendor documentation, verified on the date stamped at the top of this page.